Compare Stocks: RNTX, ALXO, ELDN, and FATE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.99 -2.5%	$1.96	$0.96 ▼ $2.66	$275.17M	0.42	1.04 million shs	273,462 shs
ELDN Eledon Pharmaceuticals	$3.41 -1.2%	$3.73	$1.35 ▼ $4.60	$277.10M	0.98	1.22 million shs	1.14 million shs
FATE Fate Therapeutics	$2.44 +4.7%	$2.56	$0.93 ▼ $3.23	$292.36M	2.52	2.62 million shs	1.31 million shs
RNTX Rein Therapeutics	$0.80 -2.2%	$0.87	$0.69 ▼ $2.18	$69.01M	1.39	445,064 shs	463,411 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	0.00%	+4.08%	+0.49%	+3.03%	+74.36%
ELDN Eledon Pharmaceuticals	0.00%	-2.54%	-3.63%	-11.31%	+32.69%
FATE Fate Therapeutics	0.00%	-9.34%	-3.32%	+3.56%	+102.61%
RNTX Rein Therapeutics	0.00%	+1.49%	+3.37%	-20.58%	-35.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.99 -2.5%	$1.96	$0.96 ▼ $2.66	$275.17M	0.42	1.04 million shs	273,462 shs
ELDN Eledon Pharmaceuticals	$3.41 -1.2%	$3.73	$1.35 ▼ $4.60	$277.10M	0.98	1.22 million shs	1.14 million shs
FATE Fate Therapeutics	$2.44 +4.7%	$2.56	$0.93 ▼ $3.23	$292.36M	2.52	2.62 million shs	1.31 million shs
RNTX Rein Therapeutics	$0.80 -2.2%	$0.87	$0.69 ▼ $2.18	$69.01M	1.39	445,064 shs	463,411 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	0.00%	+4.08%	+0.49%	+3.03%	+74.36%
ELDN Eledon Pharmaceuticals	0.00%	-2.54%	-3.63%	-11.31%	+32.69%
FATE Fate Therapeutics	0.00%	-9.34%	-3.32%	+3.56%	+102.61%
RNTX Rein Therapeutics	0.00%	+1.49%	+3.37%	-20.58%	-35.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	131.74% Upside
ELDN Eledon Pharmaceuticals	2.50	Moderate Buy	$9.67	188.13% Upside
FATE Fate Therapeutics	2.38	Hold	$5.90	147.38% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	664.33% Upside

Current Analyst Ratings Breakdown

Latest RNTX, ALXO, ELDN, and FATE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	RNTX Rein Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/7/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	ELDN Eledon Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2026	ELDN Eledon Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.35 per share	N/A
FATE Fate Therapeutics	$6.65M	42.97	N/A	N/A	$1.80 per share	1.33
RNTX Rein Therapeutics	N/A	N/A	$0.05 per share	14.31	($1.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
ELDN Eledon Pharmaceuticals	-$45.62M	-$0.91	N/A	N/A	N/A	N/A	-149.63%	-50.84%	N/A
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A

Latest RNTX, ALXO, ELDN, and FATE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
ELDN Eledon Pharmaceuticals	N/A	7.90	7.90
FATE Fate Therapeutics	N/A	4.85	4.85
RNTX Rein Therapeutics	N/A	4.27	4.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ELDN Eledon Pharmaceuticals	56.77%
FATE Fate Therapeutics	97.54%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
ELDN Eledon Pharmaceuticals	9.60%
FATE Fate Therapeutics	4.74%
RNTX Rein Therapeutics	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
ELDN Eledon Pharmaceuticals	10	81.26 million	73.46 million	Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
RNTX Rein Therapeutics	9	86.27 million	84.97 million	N/A

RNTX, ALXO, ELDN, and FATE Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for RNTX FY2026 Earnings

August 22 at 1:58 AM | americanbankingnews.com

HC Wainwright Has Bullish Outlook for RNTX FY2030 Earnings

August 21 at 3:17 AM | americanbankingnews.com

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

August 20, 2026 | globenewswire.com

Equities Analysts Set Expectations for RNTX FY2026 Earnings

August 20, 2026 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Rein Therapeutics (NASDAQ:RNTX)

August 20, 2026 | americanbankingnews.com

What is HC Wainwright's Estimate for RNTX FY2030 Earnings?

August 19, 2026 | marketbeat.com

Analysts Set Rein Therapeutics Inc. (NASDAQ:RNTX) PT at $6.00

August 19, 2026 | americanbankingnews.com

Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright

August 18, 2026 | marketbeat.com

Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results

August 14, 2026 | marketbeat.com

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026 | globenewswire.com

Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages

August 14, 2026 | marketbeat.com

Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9% - Here's Why

August 10, 2026 | marketbeat.com

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

August 4, 2026 | finance.yahoo.com

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

July 21, 2026 | globenewswire.com

Rein Therapeutics (RNTX) Stock Forecast & Price Target

July 17, 2026 | investing.com

Rein Therapeutics, Inc

June 29, 2026 | edition.cnn.com

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy

June 17, 2026 | zacks.com

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

June 11, 2026 | globenewswire.com

Rein Therapeutics Inc RNTX

June 7, 2026 | morningstar.comM

Rein Therapeutics (NASDAQ:RNTX) Director Buys $16,747.50 in Stock

May 29, 2026 | insidertrades.com

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

May 18, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ALXO, ELDN, and FATE Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.99 -0.05 (-2.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 0.00 (-0.25%)

As of 04:10 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.41 -0.04 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$3.41 0.00 (0.00%)

As of 04:20 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Fate Therapeutics NASDAQ:FATE

$2.44 +0.11 (+4.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 -0.02 (-1.02%)

As of 04:18 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Rein Therapeutics NASDAQ:RNTX

$0.80 -0.02 (-2.20%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 +0.01 (+0.63%)

As of 04:14 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, ALXO, ELDN, and FATE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, ALXO, ELDN, and FATE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, ALXO, ELDN, and FATE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ALXO, ELDN, and FATE Company Descriptions

ALX Oncology NASDAQ:ALXO

Eledon Pharmaceuticals NASDAQ:ELDN

Fate Therapeutics NASDAQ:FATE

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, ALXO, ELDN, and FATE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, ALXO, ELDN, and FATE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, ALXO, ELDN, and FATE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ALXO, ELDN, and FATE Company Descriptions

ALX Oncology NASDAQ:ALXO

Eledon Pharmaceuticals NASDAQ:ELDN

Fate Therapeutics NASDAQ:FATE

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools